A joint initiative between a Singapore-based medical technology company and Duke University is aiming to develop and commercialize artificial intelligence,…
Andrea Lobo
Andrea Lobo is a Science writer at BioNews. She holds a Biology degree and a PhD in Cell Biology/Neurosciences from the University of Coimbra-Portugal, where she studied stroke biology. She was a postdoctoral and senior researcher at the Institute for Research and Innovation in Health in Porto, in drug addiction, studying neuronal plasticity induced by amphetamines. As a research scientist for 19 years, Andrea participated in academic projects in multiple research fields, including stroke, gene regulation, cancer, and rare diseases. She authored multiple research papers in peer-reviewed journals. She shifted towards a career in science writing and communication in 2022.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Andrea Lobo
Gradient Denervation Technologies has raised €14 million (around $14.9 million) in funding to support the clinical development and testing…
Treatment with treprostinil improved the risk profile in people with inoperable or persistent severe chronic thromboembolic pulmonary hypertension (CTEPH).
Echocardiography, a noninvasive imaging method to examine heart structure and function, can be useful in making a preliminary diagnosis of…
About one-quarter of the pulmonary arterial hypertension (PAH) patients in a small study showed cognitive deficits, typically mild impairments…
Babies born preterm, or before 37 weeks of pregnancy, were shown to have a higher risk of developing pulmonary…
Tailored educational videos on healthy eating coupled with online instruction led to helpful dietary changes in a group of…
Algorithm Sciences, which is developing PulmoProst to treat pulmonary arterial hypertension (PAH), has acquired all assets of…
Tenax Therapeutics has received a notice of allowance from the U.S. Patent and Trademark Office (USPTO), indicating that a…
Team PHenomenal Hope will host its inaugural symposium — PHenomenal Hope 2023: Knowledge, Research & Advocacy in PH —…
Treatment with levosimendan — a medication seen to improve cardiac function — was associated with rapid clinical benefits in…
Among people with pulmonary arterial hypertension (PAH), a measure of artery deformity called pulmonary artery longitudinal strain may be…